![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Pharmaceutics (N.I., K.E.T.) and Department of Medicinal Chemistry (K.L.K., K.E.A., W.L.N.), University of Washington, Seattle US.
Itraconazole (ITZ) is a potent inhibitor of CYP3A in vivo. However, unbound plasma concentrations of ITZ are much lower than its reported in vitro Ki, and no clinically significant interactions would be expected based on a reversible mechanism of inhibition. The purpose of this study was to evaluate the reasons for the in vitro-in vivo discrepancy. The metabolism of ITZ by CYP3A4 was studied. Three metabolites were detected: hydroxy-itraconazole (OH-ITZ), a known in vivo metabolite of ITZ, and two new metabolites: keto-itraconazole (keto-ITZ) and N-desalkyl-itraconazole (ND-ITZ). OHITZ and keto-ITZ were also substrates of CYP3A4. Using a substrate depletion kinetic approach for parameter determination, ITZ exhibited an unbound Km of 3.9 nM and an intrinsic clearance (CLint) of 69.3 ml·min-1·nmol CYP3A4-1. The respective unbound Km values for OH-ITZ and keto-ITZ were 27 nM and 1.4 nM and the CLint values were 19.8 and 62.5 ml·min-1·nmol CYP3A4-1. Inhibition of CYP3A4 by ITZ, OH-ITZ, keto-ITZ, and ND-ITZ was evaluated using hydroxylation of midazolam as a probe reaction. Both ITZ and OH-ITZ were competitive inhibitors of CYP3A4, with unbound Ki (1.3 nM for ITZ and 14.4 nM for OH-ITZ) close to their respective Km. ITZ, OH-ITZ, keto-ITZ and ND-ITZ exhibited unbound IC50 values of 6.1 nM, 4.6 nM, 7.0 nM, and 0.4 nM, respectively, when coincubated with human liver microsomes and midazolam (substrate concentration < Km). These findings demonstrate that ITZ metabolites are as potent as or more potent CYP3A4 inhibitors than ITZ itself, and thus may contribute to the inhibition of CYP3A4 observed in vivo after ITZ dosing.
This article has been cited by other articles:
|
|
 |
|
  G. R. Tonn, S. G. Wong, S. C. Wong, M. G. Johnson, J. Ma, R. Cho, L. C. Floren, K. Kersey, K. Berry, A. P. Marcus, et al. An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple Dosing Drug Metab. Dispos., March 1, 2009; 37(3): 502 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wei, G. Dai, Z. Liu, H. Cheng, Z. Xie, R. Klisovic, G. Marcucci, and K. K. Chan Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase Drug Metab. Dispos., November 1, 2008; 36(11): 2227 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perrin, C. Aninat, V. Hamon, Y. Hayashi, C. Abadie, B. Heyd, F. Andre, and M. Delaforge Metabolism of Phenylahistin Enantiomers by Cytochromes P450: A Possible Explanation for Their Different Cytotoxicity Drug Metab. Dispos., November 1, 2008; 36(11): 2381 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Quinney, R. E. Galinsky, V. A. Jiyamapa-Serna, Y. Chen, M. A. Hamman, S. D. Hall, and R. E. Kimura Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats Drug Metab. Dispos., June 1, 2008; 36(6): 1097 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Abdel-Rahman, R. F. Jacobs, J. Massarella, R. E. Kauffman, J. S. Bradley, H. C. Kimko, G. L. Kearns, K. Shalayda, C. Curtin, S. D. Maldonado, et al. Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-{beta}-Cyclodextrin in Infants, Children, and Adolescents Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2668 - 2673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhao, C. A. Lee, and K. L. Kunze Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A Drug Metab. Dispos., May 1, 2007; 35(5): 704 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Dennison, D. R. Jones, J. L. Renbarger, and S. D. Hall Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 553 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Leveque and F. Jehl Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids J. Clin. Pharmacol., May 1, 2007; 47(5): 579 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ogasawara, T. Kume, and E. Kazama Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys Drug Metab. Dispos., March 1, 2007; 35(3): 410 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nath and W. M. Atkins A Theoretical Validation of the Substrate Depletion Approach to Determining Kinetic Parameters Drug Metab. Dispos., September 1, 2006; 34(9): 1433 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takeda, Y. Kitajima, Y. Ishii, Y. Nishimura, P. I. Mackenzie, K. Oguri, and H. Yamada INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE Drug Metab. Dispos., August 1, 2006; 34(8): 1277 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Turgeon, C. Pharand, and V. Michaud Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism Can. Med. Assoc. J., June 6, 2006; 174(12): 1729 - 1729. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Kunze, W. L. Nelson, E. D. Kharasch, K. E. Thummel, and N. Isoherranen STEREOCHEMICAL ASPECTS OF ITRACONAZOLE METABOLISM IN VITRO AND IN VIVO Drug Metab. Dispos., April 1, 2006; 34(4): 583 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galetin, K. Ito, D. Hallifax, and J. B. Houston CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 180 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
